Want to join the conversation?
$ESRX 2Q15 Q&A: Eric of Barclays: You've demonstrated your ability to impact access as we think about the 2016 formulary. What type of role does exclusion have? George, CEO: With respect to our formulary, we're still working on. We'll be rolling them out here shortly and when we do that we will talk about that on our next quarter.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.